R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Trials and tribulations of drug development: What does it ta...

Rare diseases are a complex and challenging area of medicine, affecting millions of people worldwide.

R&D

Challenges of analytical method validation for ATMPs

Quality control of medicinal products is a fundamental aspect of assuring the quality, efficacy, and safety of the product.

R&D

How are clinical trials becoming more environmentally friend...

While patient centricity remains vital to the life sciences industry, as companies come under pressure to reduce their carbon footprint, we are increasingly seeing different aspects of the

R&D

The World Without Disease Summit live coverage

The World Without Disease: Live Coverage

The inaugural World Without Disease Summit is final

R&D

How to transition from lab to commercial-scale ATMP Manufact...

This is the first article of our series, “The ATMP Manufacturer’s Guide to Commercialisation and cGMP Compliance”.

R&D

A World Without Disease – AstraZeneca and the Health Works I...

Ahead of the inaugural World Without Disease Summit on Wednesday 21st June, pharmaphorum spoke with the event’s two speakers from AstraZeneca, Stefan Woxström, SVP Europe and Canada, and Stefan Vlachos, Head of Health Works